Annual report pursuant to Section 13 and 15(d)

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - RESTATED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Details)

v3.24.3
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - RESTATED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Balance beginning $ (8,387,900) $ 1,370,983 $ 8,153,244 $ 17,912,049 $ 23,127,139 $ 29,063,131 $ 8,153,244 $ 29,063,131 $ 8,153,244 $ 29,063,131 $ 8,153,244 $ 29,063,131
Balance beginning Series D preferred stock     1,382,023       1,382,023   1,382,023   1,382,023  
Balance beginning Series D preferred stock (in shares)                        
Stock-based compensation (Note7) 497,878 419,757 408,206 367,759 419,953 303,805         2,410,288 $ 1,452,964
Exercise of warrants into common shares 649,250                   2,467,222  
Reclassification of pre-funded warrants to liability (3,239,112)                   $ (3,239,112)  
Stock awards (Note 7) (in shares)                     1,617,000 440,250
NET LOSS 17,520,378 10,178,640 7,190,470 7,511,322 5,635,043 6,239,797 17,369,110 11,874,840 34,889,488 19,386,162 $ 42,770,610 $ 31,792,618
Issuance of common stock and pre-funded warrants net of issuance costs                       9,429,767
Balance ending Series D preferred stock 19,202,023     1,382,023         19,202,023 1,382,023 $ 1,382,023 1,382,023
Balance ending Series D preferred stock (in shares)                     111.11  
Balance ending (28,000,262) (8,387,900) 1,370,983 10,768,486 17,912,049 23,127,139 (8,387,900) 17,912,049 (28,000,262) 10,768,486 $ (15,158,968) 8,153,244
As previously reported                        
Balance beginning (467,004) 7,334,461 15,507,519 20,194,072 27,209,162 33,045,154 15,507,519 33,045,154 15,507,519 33,045,154 15,507,519 33,045,154
Stock-based compensation (Note7) 497,878 419,757 408,206 367,759 419,953 303,805         2,410,288 1,452,964
Exercise of warrants into common shares 348,638                   789,642  
NET LOSS 13,732,350 8,221,222 8,581,267 7,811,322 7,435,043 6,139,797 16,802,489 13,574,840 30,534,839 21,386,162 37,983,496 28,601,254
Issuance of common stock and pre-funded warrants net of issuance costs                     17,920,000 9,610,655
Balance ending Series D preferred stock 17,920,000               17,920,000      
Balance ending (13,352,838) (467,004) 7,334,461 12,750,509 20,194,072 27,209,162 (467,004) 20,194,072 (13,352,838) 12,750,509 (1,356,047) 15,507,519
Restatement adjustments                        
Balance beginning (7,920,896) (5,963,478) (7,354,275) (2,282,023) (4,082,023) (3,982,023) (7,354,275) (3,982,023) (7,354,275) (3,982,023) (7,354,275) (3,982,023)
Balance beginning Series D preferred stock     1,382,023       1,382,023   1,382,023   1,382,023  
Exercise of warrants into common shares 300,612                   1,677,580  
Reclassification of pre-funded warrants to liability (3,239,112)                   (3,239,112) (7,005,493)
NET LOSS 3,788,028 1,957,418 (1,390,797) (300,000) (1,800,000) 100,000 566,621 (1,700,000) 4,354,649 (2,000,000) 4,787,114 3,191,364
Balance ending Series D preferred stock 1,282,023     1,382,023         1,282,023 1,382,023 1,382,023 1,382,023
Balance ending $ (14,647,424) (7,920,896) (5,963,478) (1,982,023) (2,282,023) (4,082,023) (7,920,896) (2,282,023) (14,647,424) (1,982,023) (13,802,921) (7,354,275)
Series D Preferred stock                        
Balance beginning Series D preferred stock     $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023
Balance beginning Series D preferred stock (in shares)     111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11
Balance ending Series D preferred stock       $ 1,382,023 $ 1,382,023 $ 1,382,023   $ 1,382,023   $ 1,382,023 $ 1,382,023 $ 1,382,023
Balance ending Series D preferred stock (in shares) 111.11     111.11 111.11 111.11   111.11 111.11 111.11 111.11 111.11
Series D Preferred stock | Restatement adjustments                        
Balance beginning Series D preferred stock     $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023
Balance beginning Series D preferred stock (in shares)     111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11
Balance ending Series D preferred stock       $ 1,382,023 $ 1,382,023 $ 1,382,023   $ 1,382,023   $ 1,382,023 $ 1,382,023 $ 1,382,023
Balance ending Series D preferred stock (in shares)       111.11 111.11 111.11   111.11   111.11 111.11 111.11
Series E-1 preferred stock                        
Balance ending Series D preferred stock (in shares) 1,225               1,225      
Series E-2 Preferred Stock                        
Aggregate value of shares issued                     $ 17,820,000  
Series E-2 Preferred Stock | Restatement adjustments                        
Aggregate value of shares issued                     (100,000)  
Preferred Stock                        
Balance beginning                        
Balance beginning (in shares)                        
Conversion of preferred stock to common stock                     $ (13,142,368)  
Conversion of preferred stock to common stock (in shares)                     (905.24)  
Balance ending                     $ 4,677,632  
Balance ending (in shares)                     319.76  
Preferred Stock | As previously reported                        
Balance beginning $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023
Balance beginning (in shares) 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11
Conversion of preferred stock to common stock                     $ (13,242,368)  
Conversion of preferred stock to common stock (in shares)                     (905.24)  
Issuance of common stock and pre-funded warrants net of issuance costs                     $ 17,920,000  
Issuance of common stock and pre-funded warrants net of issuance costs (in shares)                     1,225.00  
Balance ending $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 1,382,023 $ 6,059,655 $ 1,382,023
Balance ending (in shares) 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11 111.11 430.87 111.11
Preferred Stock | Restatement adjustments                        
Balance beginning $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023)
Balance beginning (in shares) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11)
Conversion of warrants into common shares                     $ 100,000  
Balance ending $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023) $ (1,382,023)
Balance ending (in shares) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11) (111.11)
Preferred Stock | Series E-1 preferred stock                        
Aggregate value of shares issued $ 17,820,000                      
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) 1,225.00                      
Preferred Stock | Series E-1 preferred stock | As previously reported                        
Aggregate value of shares issued $ 17,920,000                      
Issuance of common stock and pre-funded warrants net of issuance costs (in shares) 1,225.00                      
Preferred Stock | Series E-1 preferred stock | Restatement adjustments                        
Aggregate value of shares issued $ (100,000)                      
Preferred Stock | Series E-2 Preferred Stock                        
Shares issued                     1,225.00  
Aggregate value of shares issued                     $ 17,820,000  
Issuance of common stock and pre-funded warrants net of issuance costs (in shares)                     1,225.00  
Preferred Stock | Series E-2 Preferred Stock | Restatement adjustments                        
Aggregate value of shares issued                     $ (100,000)  
Common Stock                        
Balance beginning $ 97 $ 97 $ 94 $ 61 $ 61 $ 61 $ 94 $ 61 $ 94 $ 61 $ 94 $ 61
Balance beginning (in shares) 9,740,507 9,740,507 9,385,272 6,110,122 6,110,124 6,110,125 9,385,272 6,110,125 9,385,272 6,110,125 9,385,272 6,110,125
Exercise of warrants into common shares $ 2                   $ 12  
Exercise of warrants into common shares (in shares) 177,877                   1,197,622  
Conversion of preferred stock to common stock                     $ 99  
Conversion of preferred stock to common stock (in shares)                     9,947,684  
Stock awards (Note 7)                     $ 2  
Stock awards (Note 7) (in shares)                     213,532  
Retired shares (in shares)       (4) (2) (1)           6
Issuance of common stock and pre-funded warrants net of issuance costs                       $ 33
Issuance of common stock and pre-funded warrants net of issuance costs (in shares)                       3,275,153
Balance ending $ 99 $ 97 $ 97 $ 61 $ 61 $ 61 $ 97 $ 61 $ 99 $ 61 $ 207 $ 94
Balance ending (in shares) 9,918,384 9,740,507 9,740,507 6,110,118 6,110,122 6,110,124 9,740,507 6,110,122 9,918,384 6,110,118 20,744,110 9,385,272
Common Stock | As previously reported                        
Balance beginning $ 97 $ 97 $ 94 $ 61 $ 61 $ 61 $ 94 $ 61 $ 94 $ 61 $ 94 $ 61
Balance beginning (in shares) 9,740,507 9,740,507 9,385,272 6,110,122 6,110,124 6,110,125 9,385,272 6,110,125 9,385,272 6,110,125 9,385,272 6,110,125
Exercise of warrants into common shares $ 2                   $ 12  
Exercise of warrants into common shares (in shares) 177,877                   1,197,622  
Conversion of preferred stock to common stock                     $ 99  
Conversion of preferred stock to common stock (in shares)                     9,947,684  
Stock awards (Note 7)                     $ 2  
Stock awards (Note 7) (in shares)                     213,532  
Retired shares (in shares)       (4) (2) (1)           (6)
Issuance of common stock and pre-funded warrants net of issuance costs                       $ 33
Issuance of common stock and pre-funded warrants net of issuance costs (in shares)                       3,275,153
Balance ending $ 99 $ 97 $ 97 $ 61 $ 61 $ 61 $ 97 $ 61 $ 99 $ 61 $ 207 $ 94
Balance ending (in shares) 9,918,384 9,740,507 9,740,507 6,110,118 6,110,122 6,110,124 9,740,507 6,110,122 9,918,384 6,110,118 20,744,110 9,385,272
Additional Paid-In Capital                        
Balance beginning $ 168,971,520 $ 168,551,763 $ 168,143,557 $ 157,984,617 $ 157,564,664 $ 157,260,859 $ 168,143,557 $ 157,260,859 $ 168,143,557 $ 157,260,859 $ 168,143,557 $ 157,260,859
Stock-based compensation (Note7) $ 497,878 419,757 408,206 367,759 419,953 303,805         2,410,288 1,452,964
Exercise of warrants into common shares                     2,467,210  
Exercise of warrants into common shares (in shares) 649,248                      
Conversion of preferred stock to common stock                     13,142,269  
Reclassification of pre-funded warrants to liability $ (3,239,112)                   (3,239,112)  
Stock awards (Note 7)                     (2)  
Issuance of common stock and pre-funded warrants net of issuance costs                       9,429,734
Balance ending 166,879,534 168,971,520 168,551,763 158,352,376 157,984,617 157,564,664 168,971,520 157,984,617 166,879,534 158,352,376 182,924,210 168,143,557
Additional Paid-In Capital | As previously reported                        
Balance beginning 194,452,408 194,032,651 193,624,445 183,284,617 182,864,664 182,560,859 193,624,445 182,560,859 193,624,445 182,560,859 193,624,445 182,560,859
Stock-based compensation (Note7) 497,878 419,757 408,206 367,759 419,953 303,805         2,410,288 1,452,964
Exercise of warrants into common shares 348,636                   789,630  
Conversion of preferred stock to common stock                     13,242,269  
Stock awards (Note 7)                     (2)  
Issuance of common stock and pre-funded warrants net of issuance costs                       9,610,622
Balance ending 195,298,922 194,452,408 194,032,651 183,652,376 183,284,617 182,864,664 194,452,408 183,284,617 195,298,922 183,652,376 210,066,630 193,624,445
Additional Paid-In Capital | Restatement adjustments                        
Balance beginning (25,480,888) (25,480,888) (25,480,888) (25,300,000) (25,300,000) (25,300,000) (25,480,888) (25,300,000) (25,480,888) (25,300,000) (25,480,888) (25,300,000)
Exercise of warrants into common shares 300,612                   1,677,580  
Reclassification of pre-funded warrants to liability (3,239,112)                   (3,239,112) (7,005,493)
Conversion of warrants into common shares                     (100,000)  
Balance ending (28,419,388) (25,480,888) (25,480,888) (25,300,000) (25,300,000) (25,300,000) (25,480,888) (25,300,000) (28,419,388) (25,300,000) (27,142,420) (25,480,888)
Accumulated Deficit                        
Balance beginning (177,359,517) (167,180,877) (159,990,407) (140,072,629) (134,437,586) (128,197,789) (159,990,407) (128,197,789) (159,990,407) (128,197,789) (159,990,407) (128,197,789)
NET LOSS 17,520,378 10,178,640 7,190,470 7,511,322 5,635,043 6,239,797         42,770,610 31,792,618
Balance ending (194,879,895) (177,359,517) (167,180,877) (147,583,951) (140,072,629) (134,437,586) (177,359,517) (140,072,629) (194,879,895) (147,583,951) (202,761,017) (159,990,407)
Accumulated Deficit | As previously reported                        
Balance beginning (196,301,532) (188,080,310) (179,499,043) (164,472,629) (157,037,586) (150,897,789) (179,499,043) (150,897,789) (179,499,043) (150,897,789) (179,499,043) (150,897,789)
NET LOSS 13,732,350 8,221,222 8,581,267 7,811,322 7,435,043 6,139,797         37,983,496 28,601,254
Balance ending (210,033,882) (196,301,532) (188,080,310) (172,283,951) (164,472,629) (157,037,586) (196,301,532) (164,472,629) (210,033,882) (172,283,951) (217,482,539) (179,499,043)
Accumulated Deficit | Restatement adjustments                        
Balance beginning 18,942,015 20,899,433 19,508,636 24,400,000 22,600,000 22,700,000 19,508,636 22,700,000 19,508,636 22,700,000 19,508,636 22,700,000
NET LOSS 3,788,028 1,957,418 (1,390,797) (300,000) (1,800,000) 100,000         4,787,114 3,191,364
Balance ending $ 15,153,987 $ 18,942,015 20,899,433 $ 24,700,000 $ 24,400,000 $ 22,600,000 $ 18,942,015 $ 24,400,000 $ 15,153,987 $ 24,700,000 $ 14,721,522 19,508,636
Pre-funded warrants                        
Conversion of warrants into common shares     3                  
Pre-funded warrants | As previously reported                        
Conversion of warrants into common shares     3                  
Pre-funded warrants | Common Stock                        
Conversion of warrants into common shares     $ 3                  
Conversion of warrants into common shares (in shares)     355,235                  
Pre-funded warrants | Common Stock | As previously reported                        
Conversion of warrants into common shares     $ 3                  
Conversion of warrants into common shares (in shares)     355,235                  
Warrants | Restatement adjustments                        
Issuance of common stock and pre-funded warrants net of issuance costs                       6,824,605
Warrants | Additional Paid-In Capital | Restatement adjustments                        
Issuance of common stock and pre-funded warrants net of issuance costs                       $ 6,824,605